The Synthetic Biology Market size was estimated at USD 13.1 billion in 2022 and is expected to reach USD 52.6 billion by 2030 at a CAGR of 19.0% during the forecast period of 2023-2030.
Synthetic biology combines engineering and science to build novel biological systems with practical applications. Synthetic biology is the process of producing new biological units such as cells, enzymes, and genetic circuits as well as changing existing biological systems. The basic purpose of synthetic biology is to generate new biological components that do not exist in nature, such as advanced biofuels, renewable chemicals, and bio products. Synthetic biology discovers standardised genomic units that may be used to quickly synthesize and assemble small genomic elements into integrated big systems to address specific biological problems for the development of biological systems.
Get more information on Synthetic Biology Market - Request Free Sample Report
DRIVERS
Increased funding is likely to drive the market growth
The depletion of the antibiotic pipeline, the rising incidence of chronic and debilitating diseases such as cancer and HIV, and the growing need to develop effective and promising cures for a variety of diseases that have a negative impact on people's quality of life around the world have all fueled interest in synthetic biomedicine research. The constant increase in government financing for synthetic biology is boosting the market's expansion. For example, in July 2022, SynBioVen, committed to funding SynbiCITE, the UK's National Centre for the Industrial Translation of Synthetic Biology, in July 2022. SynBioVen is a venture capital investment firm situated in the United Kingdom that was founded in 2022. The organization primarily invests in the healthcare and biotechnology sectors. The investment will allow the Imperial-hosted institute to continue to promote synthetic biology entrepreneurs and SMEs, as well as to boost the burgeoning UK bioeconomy and uncover the societal advantages of synthetic biology.
RESTRAIN
Biosafety, biosecurity, and ethical concerns
The deliberate or unintentional release of synthetic organisms into the environment during research and other uses is an essential biosafety concept in synthetic biology. When synthetic bacteria are introduced into the environment, they can mutate or interact with other organisms, resulting in crossbreeding with natural creatures and bio errors. This can endanger the natural species' environment. Another major biosafety worry is the development of antibiotic-resistant superbugs. In recent years, the European Union (EU) has supported various research projects on the environmental impact of purposely released genetically altered bacteria for plant growth or bioremediation.
OPPORTUNITY
Application of Machine Learning to Research and Development
In recent years, artificial intelligence (Al)/ machine learning has emerged as a viable alternative to systems biology for elucidating biological phenomena and achieving specific design goals in synthetic biology. The present advancement of artificial intelligence (Al) and machine learning (ML) techniques and tools in biological and biotechnological domains can be regarded similarly in terms of bringing smarter and more automated analysis and decision-making to these sectors. Al/ML remains an option for researching system dynamics and enhancing output in synthetic biology applications. Currently, several industry participants are focusing on the use of machine learning in synthetic biology. There is also massive government support. This will almost certainly provide attractive growth prospects in the next years.
CHALLENGES
Risk associated with synthetic biology
As the Ukraine situation worsens, healthcare businesses are experiencing unprecedented hurdles in manufacturing, access, and supply chain. Naturally, personnel safety and patient access to crucial pharmaceuticals and supplies are high issues for firms working in or with Ukraine. Aside from that, there is a possibility of long-term disruption in global supply chains, such as an increase in the cost of raw materials and logistics. Medical technology firms, in particular, are suffering challenges as freight and shipping prices rise.
IMPACT OF ONGOING RECESSION
The COVID-19 epidemic substantially slowed the flow of people, goods, and services around the world, particularly in countries where Illumina, Inc. sells products and services and does business. COVID-19's impact on business activity in the future cannot be predicted with any certainty, but it may have a negative impact on demand for company products and services, limit company sales operations, marketing efforts, and customer field support, impede product shipping and delivery to customers, disrupt supply chain, and limit ability to conduct research and product development, among other important business activities.
By Technology
NGS Technology
PCR Technology
Genome Editing Technology
Bioprocessing Technology
Other Technologies
In 2022, PCR Technology segment is expected to held the highest market share of 27.3% during the forecast period. Polymerase Chain Reaction (PCR) has developed as a crucial technology for detecting and analyzing specific gene sequences. Real-time PCR tests have great sensitivity and specificity, making them the preferred approach for many PCR-based genomic research. This approach is commonly utilized in forensic research, DNA cloning, molecular diagnostics, and genomics.
By Product
Oligonucleotide/Oligo Pools and Synthetic DNA
Enzymes
Cloning Technologies Kits
Xeno-Nucleic Acids
Chassis Organism
Oligonucleotide/Oligo Pools and Synthetic DNA segment is generating revenue of 4,754 million in 2022, during the forecast period. Oligonucleotides are the key point of contact in various molecular and synthetic biology applications. Increased use of targeted NGS, mutagenesis experiments, DNA computing, and CRISPR gene editing are the key sector drivers. OligoMix, for example, is an innovative and personalized option for genomics research. The synthesis of numerous oligonucleotide sequences is massively parallelized. The corresponding cost per base is less than 0.8 cents.
By Application
Healthcare
Clinical
Non-Clinical
Non-healthcare
Biotech Crops
Specialty Chemicals
Bio-fuels
Others
In 2022, the healthcare segment is expected to dominate the market growth of 19.3% during the forecast period. Infectious microorganisms, cancer cells, and pharmaceuticals can all be identified using synthetic biology diagnostics, which are highly specific, sensitive, real-time, and non-invasive. Dynamic bio-sensing systems with a CPU, sensor, and reporter are created using rational engineering principles.
The segment is also being drive by an increase in neurological illnesses such as multiple sclerosis. For example, as of July 2022, scientists in synthetic biology at the University of Toronto Engineering are generating unique stem cells from patient tissues to treat ailments. Such research initiatives are expected to augment segment growth.
By End User
Biotechnology and Pharmaceutical Companies
Academic and Government Research Institutes
Others
Need any customization research on Synthetic Biology Market - Enquiry Now
In 2022, Pharmaceutical & Biotechnology Companies segment is expected to dominate the market growth of 51.7% during the forecast period due to Synthetic biology has benefited biotech and pharmaceutical businesses in the creation of new chronic disease therapies. Merck, for example, developed Januvia (sitagliptin), a diabetes medication, using synthetic biology techniques. Novartis also introduced Kymriah (Tisagenlecleucel) to treat B-cell acute lymphoblastic leukemia.
North America held a significant market share growing with a highest CAGR of 41.3% in 2022 owing to increased private-sector investment, favorable laws, and government aid. The United States focuses mostly on proteomics, drug screening and discovery, and genomes structure prediction research, which drives the expansion of the synthetic biology business.
Asia-Pacific is witness to expand fastest CAGR rate during the forecast period due to the rising investments in Asia Pacific countries, increased partnerships and funding in the Chinese market, and increased collaborations in the field of synthetic biology are some of the reasons expected to drive the growth of the synthetic biology market. Furthermore, a number of Asian countries have lately established national institutes, state-sponsored research programs, and academia-industry alliances to foster technical innovation for the advancement of synthetic biology.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Bota Biosciences Inc., Codexis, Inc., Creative Biogene., Creative Enzymes., Enbiotix, Inc., Illumina, Inc., Merck Kgaa (Sigma-Aldrich Co. Llc), New England Biolabs, Euro fins Scientific, Novozymes, Pareto Bio, Inc., Synthetic Genomics Inc., Thermo Fisher Scientific, Inc., and Others.
Biogene, in November 2021, to accelerate RNAi research, Creative Biogene offered a wide range of shRNA products. The company has extensive expertise and experience in providing high-quality RNAi products such as shRNA clones and siRNA libraries, with the goal of providing effective, convenient, and dependable tools to accelerate RNAi research.
Novozymes, in January 2021, Novozymes introduced Frontia GlutenEx. It would assist wheat processors in increasing gluten protein recovery while reducing energy usage.
Merck, in February 2021, Merck collaborated with BioNTech (Germany) to provide lipids for the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2).
Merck, in January 2021, Merck purchased AmpTec (Germany). With this acquisition, the company expanded its product offering to include mRNA for use in vaccines, therapies, and diagnostics.
| Report Attributes | Details |
| Market Size in 2022 | US$ 13.1 Billion |
| Market Size by 2030 | US$ 52.6 Billion |
| CAGR | CAGR of 19.0% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2019-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology (NGS Technology, PCR Technology, Genome Editing Technology, Bioprocessing Technology, Other Technologies) • By Product (Oligonucleotide/Oligo Pools and Synthetic DNA, Enzymes, Cloning Technologies Kits, Xeno-Nucleic Acids, Chassis Organism) • By Application (Healthcare, Non-healthcare) • By End User (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Bota Biosciences Inc., Codexis, Inc., Creative Biogene., Creative Enzymes., Enbiotix, Inc., Illumina, Inc., Merck Kgaa (Sigma-Aldrich Co. Llc), New England Biolabs, Euro fins Scientific, Novozymes, Pareto Bio, Inc., Synthetic Genomics Inc., Thermo Fisher Scientific, Inc. |
| Key Drivers | • Increased funding is likely to drive the market growth |
| Market Restrain | • Biosafety, biosecurity, and ethical concerns |
Ans: The synthetic biology Market is expected to grow at 19.0% CAGR from 2023 to 2030.
Ans: According to our analysis, the synthetic biology market is anticipated to reach USD 52.6 billion by 2030.
Ans: Increasing funding for research and development.
Ans. North America lead a significant market share growing with a highest CAGR of 41.3% in 2022.
Ans: Yes, you may request customization based on your company's needs.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Synthetic Biology Market Segmentation, by Technology
8.1NGS Technology
8.2PCR Technology
8.3Genome Editing Technology
8.4Bioprocessing Technology
8.5Other Technologies
9. Synthetic Biology Market Segmentation, by Product
9.1Oligonucleotide/Oligo Pools and Synthetic DNA
9.2Enzymes
9.3Cloning Technologies Kits
9.4Xeno-Nucleic Acids
9.5Chassis Organism
10. Synthetic Biology Market Segmentation, by Application
10.1 Healthcare
10.1.1Clinical
10.1.2Non-Clinical
10.2 Non-healthcare
10.2.1Biotech Crops
10.2.2Specialty Chemicals
10.2.3Bio-fuels
10.2.4Others
11. Synthetic Biology Market Segmentation, by End User
11.1 Biotechnology and Pharmaceutical Companies
11.2 Academic and Government Research Institutes
11.3 Others
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Synthetic Biology Market by Country
12.2.2North America Synthetic Biology Market by Technology
12.2.3 North America Synthetic Biology Market by Product
12.2.4 North America Synthetic Biology Market by Application
12.2.5 North America Synthetic Biology Market by End User
12.2.6 USA
12.2.6.1 USA Synthetic Biology Market by Technology
12.2.6.2 USA Synthetic Biology Market by Product
12.2.6.3 USA Synthetic Biology Market by Application
12.2.6.4 USA Synthetic Biology Market by End User
12.2.7 Canada
12.2.7.1 Canada Synthetic Biology Market by Technology
12.2.7.2 Canada Synthetic Biology Market by Product
12.2.7.3 Canada Synthetic Biology Market by Application
12.2.7.4 Canada Synthetic Biology Market by End User
12.2.8 Mexico
12.2.8.1 Mexico Synthetic Biology Market by Technology
12.2.8.2 Mexico Synthetic Biology Market by Product
12.2.8.3 Mexico Synthetic Biology Market by Application
12.2.8.4 Mexico Synthetic Biology Market by End User
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Synthetic Biology Market by Country
12.3.1.2 Eastern Europe Synthetic Biology Market by Technology
12.3.1.3 Eastern Europe Synthetic Biology Market by Product
12.3.1.4 Eastern Europe Synthetic Biology Market by Application
12.3.1.5 Eastern Europe Synthetic Biology Market by End User
12.3.1.6 Poland
12.3.1.6.1 Poland Synthetic Biology Market by Technology
12.3.1.6.2 Poland Synthetic Biology Market by Product
12.3.1.6.3 Poland Synthetic Biology Market by Application
12.3.1.6.4 Poland Synthetic Biology Market by End User
12.3.1.7 Romania
12.3.1.7.1 Romania Synthetic Biology Market by Technology
12.3.1.7.2 Romania Synthetic Biology Market by Product
12.3.1.7.3 Romania Synthetic Biology Market by Application
12.3.1.7.4 Romania Synthetic Biology Market by End User
12.3.1.8 Hungary
12.3.1.8.1 Hungary Synthetic Biology Market by Technology
12.3.1.8.2 Hungary Synthetic Biology Market by Product
12.3.1.8.3 Hungary Synthetic Biology Market by Application
12.3.1.8.4 Hungary Synthetic Biology Market by End User
12.3.1.9 Turkey
12.3.1.9.1 Turkey Synthetic Biology Market by Technology
12.3.1.9.2 Turkey Synthetic Biology Market by Product
12.3.1.9.3 Turkey Synthetic Biology Market by Application
12.3.1.9.4 Turkey Synthetic Biology Market by End User
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Synthetic Biology Market by Technology
12.3.1.10.2 Rest of Eastern Europe Synthetic Biology Market by Product
12.3.1.10.3 Rest of Eastern Europe Synthetic Biology Market by Application
12.3.1.10.4 Rest of Eastern Europe Synthetic Biology Market by End User
12.3.2 Western Europe
12.3.2.1 Western Europe Synthetic Biology Market by Country
12.3.2.2 Western Europe Synthetic Biology Market by Technology
12.3.2.3 Western Europe Synthetic Biology Market by Product
12.3.2.4 Western Europe Synthetic Biology Market by Application
12.3.2.5 Western Europe Synthetic Biology Market by End User
12.3.2.6 Germany
12.3.2.6.1 Germany Synthetic Biology Market by Technology
12.3.2.6.2 Germany Synthetic Biology Market by Product
12.3.2.6.3 Germany Synthetic Biology Market by Application
12.3.2.6.4 Germany Synthetic Biology Market by End User
12.3.2.7 France
12.3.2.7.1 France Synthetic Biology Market by Technology
12.3.2.7.2 France Synthetic Biology Market by Product
12.3.2.7.3 France Synthetic Biology Market by Application
12.3.2.7.4 France Synthetic Biology Market by End User
12.3.2.8 UK
12.3.2.8.1 UK Synthetic Biology Market by Technology
12.3.2.8.2 UK Synthetic Biology Market by Product
12.3.2.8.3 UK Synthetic Biology Market by Application
12.3.2.8.4 UK Synthetic Biology Market by End User
12.3.2.9 Italy
12.3.2.9.1 Italy Synthetic Biology Market by Technology
12.3.2.9.2 Italy Synthetic Biology Market by Product
12.3.2.9.3 Italy Synthetic Biology Market by Application
12.3.2.9.4 Italy Synthetic Biology Market by End User
12.3.2.10 Spain
12.3.2.10.1 Spain Synthetic Biology Market by Technology
12.3.2.10.2 Spain Synthetic Biology Market by Product
12.3.2.10.3 Spain Synthetic Biology Market by Application
12.3.2.10.4 Spain Synthetic Biology Market by End User
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Synthetic Biology Market by Technology
12.3.2.11.2 Netherlands Synthetic Biology Market by Product
12.3.2.11.3 Netherlands Synthetic Biology Market by Application
12.3.2.11.4 Netherlands Synthetic Biology Market by End User
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Synthetic Biology Market by Technology
12.3.2.12.2 Switzerland Synthetic Biology Market by Product
12.3.2.12.3 Switzerland Synthetic Biology Market by Application
12.3.2.12.4 Switzerland Synthetic Biology Market by End User
12.3.2.13 Austria
12.3.2.13.1 Austria Synthetic Biology Market by Technology
12.3.2.13.2 Austria Synthetic Biology Market by Product
12.3.2.13.3 Austria Synthetic Biology Market by Application
12.3.2.13.4 Austria Synthetic Biology Market by End User
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Synthetic Biology Market by Technology
12.3.2.14.2 Rest of Western Europe Synthetic Biology Market by Product
12.3.2.14.3 Rest of Western Europe Synthetic Biology Market by Application
12.3.2.14.4 Rest of Western Europe Synthetic Biology Market by End User
12.4 Asia-Pacific
12.4.1 Asia Pacific Synthetic Biology Market by Country
12.4.2 Asia Pacific Synthetic Biology Market by Technology
12.4.3 Asia Pacific Synthetic Biology Market by Product
12.4.4 Asia Pacific Synthetic Biology Market by Application
12.4.5 Asia Pacific Synthetic Biology Market by End User
12.4.6 China
12.4.6.1 China Synthetic Biology Market by Technology
12.4.6.2 China Synthetic Biology Market by Product
12.4.6.3 China Synthetic Biology Market by Application
12.4.6.4 China Synthetic Biology Market by End User
12.4.7 India
12.4.7.1 India Synthetic Biology Market by Technology
12.4.7.2 India Synthetic Biology Market by Product
12.4.7.3 India Synthetic Biology Market by Application
12.4.7.4 India Synthetic Biology Market by End User
12.4.8 Japan
12.4.8.1 Japan Synthetic Biology Market by Technology
12.4.8.2 Japan Synthetic Biology Market by Product
12.4.8.3 Japan Synthetic Biology Market by Application
12.4.8.4 Japan Synthetic Biology Market by End User
12.4.9 South Korea
12.4.9.1 South Korea Synthetic Biology Market by Technology
12.4.9.2 South Korea Synthetic Biology Market by Product
12.4.9.3 South Korea Synthetic Biology Market by Application
12.4.9.4 South Korea Synthetic Biology Market by End User
12.4.10 Vietnam
12.4.10.1 Vietnam Synthetic Biology Market by Technology
12.4.10.2 Vietnam Synthetic Biology Market by Product
12.4.10.3 Vietnam Synthetic Biology Market by Application
12.4.10.4 Vietnam Synthetic Biology Market by End User
12.4.11 Singapore
12.4.11.1 Singapore Synthetic Biology Market by Technology
12.4.11.2 Singapore Synthetic Biology Market by Product
12.4.11.3 Singapore Synthetic Biology Market by Application
12.4.11.4 Singapore Synthetic Biology Market by End User
12.4.12 Australia
12.4.12.1 Australia Synthetic Biology Market by Technology
12.4.12.2 Australia Synthetic Biology Market by Product
12.4.12.3 Australia Synthetic Biology Market by Application
12.4.12.4 Australia Synthetic Biology Market by End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Synthetic Biology Market by Technology
12.4.13.2 Rest of Asia-Pacific Synthetic Biology Market by Product
12.4.13.3 Rest of Asia-Pacific Synthetic Biology Market by Application
12.4.13.4 Rest of Asia-Pacific Synthetic Biology Market by End User
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Synthetic Biology Market by country
12.5.1.2 Middle East Synthetic Biology Market by Technology
12.5.1.3 Middle East Synthetic Biology Market by Product
12.5.1.4 Middle East Synthetic Biology Market by Application
12.5.1.5 Middle East Synthetic Biology Market by End User
12.5.1.6 UAE
12.5.1.6.1 UAE Synthetic Biology Market by Technology
12.5.1.6.2 UAE Synthetic Biology Market by Product
12.5.1.6.3 UAE Synthetic Biology Market by Application
12.5.1.6.4 UAE Synthetic Biology Market by End User
12.5.1.7 Egypt
12.5.1.7.1 Egypt Synthetic Biology Market by Technology
12.5.1.7.2 Egypt Synthetic Biology Market by Product
12.5.1.7.3 Egypt Synthetic Biology Market by Application
12.5.1.7.4 Egypt Synthetic Biology Market by End User
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Synthetic Biology Market by Technology
12.5.1.8.2 Saudi Arabia Synthetic Biology Market by Product
12.5.1.8.3 Saudi Arabia Synthetic Biology Market by Application
12.5.1.8.4 Saudi Arabia Synthetic Biology Market by End User
12.5.1.9 Qatar
12.5.1.9.1 Qatar Synthetic Biology Market by Technology
12.5.1.9.2 Qatar Synthetic Biology Market by Product
12.5.1.9.3 Qatar Synthetic Biology Market by Application
12.5.1.9.4 Qatar Synthetic Biology Market by End User
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Synthetic Biology Market by Technology
12.5.1.10.2 Rest of Middle East Synthetic Biology Market by Product
12.5.1.10.3 Rest of Middle East Synthetic Biology Market by Application
12.5.1.10.4 Rest of Middle East Synthetic Biology Market by End User
12.5.2. Africa
12.5.2.1 Africa Synthetic Biology Market by country
12.5.2.2 Africa Synthetic Biology Market by Technology
12.5.2.3 Africa Synthetic Biology Market by Product
12.5.2.4 Africa Synthetic Biology Market by Application
12.5.2.5 Africa Synthetic Biology Market by End User
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Synthetic Biology Market by Technology
12.5.2.6.2 Nigeria Synthetic Biology Market by Product
12.5.2.6.3 Nigeria Synthetic Biology Market by Application
12.5.2.6.4 Nigeria Synthetic Biology Market by End User
12.5.2.7 South Africa
12.5.2.7.1 South Africa Synthetic Biology Market by Technology
12.5.2.7.2 South Africa Synthetic Biology Market by Product
12.5.2.7.3 South Africa Synthetic Biology Market by Application
12.5.2.7.4 South Africa Synthetic Biology Market by End User
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Synthetic Biology Market by Technology
12.5.2.8.2 Rest of Africa Synthetic Biology Market by Product
12.5.2.8.3 Rest of Africa Synthetic Biology Market by Application
12.5.2.8.4 Rest of Africa Synthetic Biology Market by End User
12.6. Latin America
12.6.1 Latin America Synthetic Biology Market by country
12.6.2 Latin America Synthetic Biology Market by Technology
12.6.3 Latin America Synthetic Biology Market by Product
12.6.4 Latin America Synthetic Biology Market by Application
12.6.5 Latin America Synthetic Biology Market by End User
12.6.6 Brazil
12.6.6.1 Brazil Synthetic Biology Market by Technology
12.6.6.2 Brazil Synthetic Biology Market by Product
12.6.6.3 Brazil Synthetic Biology Market by Application
12.6.6.4 Brazil Synthetic Biology Market by End User
12.6.7 Argentina
12.6.7.1 Argentina Synthetic Biology Market by Technology
12.6.7.2 Argentina Synthetic Biology Market by Product
12.6.7.3 Argentina Synthetic Biology Market by Application
12.6.7.4 Argentina Synthetic Biology Market by End User
12.6.8 Colombia
12.6.8.1 Colombia Synthetic Biology Market by Technology
12.6.8.2 Colombia Synthetic Biology Market by Product
12.6.8.3 Colombia Synthetic Biology Market by Application
12.6.8.4 Colombia Synthetic Biology Market by End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Synthetic Biology Market by Technology
12.6.9.2 Rest of Latin America Synthetic Biology Market by Product
12.6.9.3 Rest of Latin America Synthetic Biology Market by Application
12.6.9.4 Rest of Latin America Synthetic Biology Market by End User
13. Company Profile
13.1 Bota Biosciences Inc.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Codexis, Inc.
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Creative Biogene.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Creative Enzymes.
13.4 Company Overview
13.4.2 Financials
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Enbiotix, Inc.
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Illumina, Inc.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Merck Kgaa (Sigma-Aldrich Co. LLC)
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 New England Biolabs
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Euro fins Scientific
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Novozymes
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
13.11 Pareto Bio, Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.11 Synthetic Genomics Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.11 Thermo Fisher Scientific, Inc.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
In 2022, The Medical Equipment Financing Market size amounted to USD 126.65 Billion & is estimated to reach USD 265.61 Billion by 2030 and increase at a compound annual growth rate of 9.7% between 2023 and 2030.
The PET-CT Scanner Device Market size was estimated USD 2.3 billion in 2022 and is expected to reach USD 4.0 billion by 2030 at a CAGR of 7.2% during the forecast period of 2023-2030.
The Pharmacovigilance Market is expected to reach USD 12.03 Bn by 2031 and was valued at USD 7.05 Bn in 2023 and simultaneously grow at a CAGR of 6.9% over the forecast period of 2024-2031.
The Genome Editing Market size was estimated USD 6.4 billion in 2022 and is expected to reach USD 23.8 billion by 2030 at a CAGR of 17.9% during the forecast period of 2023-2030.
The Cardiac Implant Market size was valued at USD 24 Bn in 2022 and is expected to reach USD 38.25 Bn in 2030 and grow at a CAGR of 6.0% over the forecast period of 2023-2030.
The Foley Catheter Market size was estimated USD 1.63 billion in 2022 and is expected to reach USD2.56 billion by 2030 at a CAGR of 5.8% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
